Vaccine responses in patients with chronic lymphocytic leukemia on treatment with Bruton Tyrosine Kinase Inhibitors: a focused review
AUTOR(ES)
Din, Mohammad Ammad Ud; Liaqat, Hania; Anwer, Faiz
FONTE
Hematology, Transfusion and Cell Therapy
DATA DE PUBLICAÇÃO
2022
RESUMO
Documentos Relacionados
- Recommendations for the management of cardiovascular risk in patients with chronic myeloid leukemia on tyrosine kinase inhibitors: risk assessment, stratification, treatment and monitoring
- Successful treatment of chronic myeloid leukemia with tyrosine kinase inhibitors goes beyond access to drugs
- Importance of adherence to BCR-ABL tyrosine-kinase inhibitors in the treatment of chronic myeloid leukemia
- Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors - a single center experience
- Serum concentrations of nitrite and malondialdehyde as markers of oxidative stress in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors